Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
  Phillip Investor Notes

19-06-2020(Fri) 18-06-2020(Thu) 17-06-2020(Wed) 16-06-2020(Tue) 15-06-2020(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
11 May, 2020 (Monday)

Health and Happiness (H&H) International Holdings (1112) announced that despite some operational challenges caused by the global pandemic, it has proactively responded to consumer demand and adapted its business model during those periods, ensuring stable supply during the lockdowns imposed in its main markets. Total revenue grew 13% on a like-for-like basis to RMB2,423.7 million in the three months ended 31 March 2020. Revenue in China posted a solid growth of 18.4%, accounting for 81.6% of total revenue, with the China market now accounting for 81.6% of its total revenue, compared with 77.2% in the same period of last year. The Group will continue to strive to deliver sustainable growth, with new product development initiatives and channel expansion remaining the two pillars of its growth strategy for 2020. (I do not hold the above stock)
Buy-in Price: $34.00, Target Price: $38.00, Cut Loss Price: $32.00

China Resources Medical Holdings Company Limited manages and operates 107 medical institutions in China and has more than 10,000 operating beds in China. The company provides general hospital services, management services for non-profitable hospital, third-party supply chain services, and GPO services. In 2019, the company's annual revenue was 2.115 billion RMB, an increase of 2.7% YoY, and reported a net profit of 391 million RMB, a YoY decline of 9.3%. But still, after the COVID 19 pandemic, with the belief that the Chinese government is going to accelerate the reformation of online medical care and associated medical insurance support, the online pharmaceutical industry and its supporting facilities will usher in a new milestone. Moreover, the management team of CR Medical also disclosed in its FY19 annual announcement that its parent company CR Healthcare has plans to incorporate more of its businesses into the CR Medical (listed company) system in the future. We look forward to the expansion of CR Medical in the future.
Buy-in Price: $3.95, Target Price: $4.40, Cut Loss Price: $3.75

Sumitomo Chemical Company, Limited (4005)
Founded in 1913 in Niihama, Ehime Prefecture. Offers products supporting the lifestyles of people and a wide range of industries globally across 5 business fields, which is petrochemistry, energy and functional materials, information electron chemistry, the health and agriculturerelated and pharmaceuticals.For 3Q (Apr-Dec) results of FY2020/3 announced on 31/1, sales revenue decreased by 3.7% to 1.6507 billion yen compared to the same period the previous year and core operating profit which indicates recurring profitability decreased by 25.0% to 116.271 billion yen. Despite an increase in revenue and an increase in core operating profit in pharmaceuticals, in their mainstay petrochemical business, net sales decreased by 10.2% and core operating profit decreased by 47.1%.For its full year plan, sales revenue is expected to increase by 0.5% to 2.33 trillion yen compared to the previous year and core operating profit to decrease by 21.7% to 160 billion yen. The company possesses listed subsidiaries such as Sumitomo Dainippon Pharma (4506) and Koei Chemical (4367), and we can expect a focus and selection of corporate groups that have gone through a resolution of parent-subsidiary listing. Also, if low crude oil prices persist, global competitiveness of petrochemical complexes will increase and we can expect this to benefit their petrochemical business.Target Price : 355 yenBuy Price : 317 yenCut-Loss : 300 yen

BYD (1211.HK) - Entering a result harvest period with multiple catalysts

Investment Summary

Obvious Characteristic of High in the Beginning and Low at the End regarding Profit in 2019

BYD recorded revenue of RMB121,780 million, basically levelled with the previous year. Net profit attributable to the parent company decreased by 42% to RMB1.6 billion. The EPS was RMB0.5, with a dividend paid of RMB0.06 per share. In the four quarters, the net profit of the Company was RMB750 million, 705 million, 120 million and 40 million, respectively, up by 236.4%, up by 24.5%, down by 80.6% and down by 84% yoy, respectively. Regarding profit, there was obvious characteristic of high in the beginning and low at the end, which was consistent with the fluctuation of domestic new energy vehicle industry which resulting from the retreat of subsidy policy and switch to China VI vehicle emission standards.

The sales volume of new energy vehicles of the Company in H1 and H2 of 2019 was 146,000 and 84,000, respectively, up by 94.5% and down by 51.5% yoy, respectively, and down by 7.4% throughout the year. The sales volume of traditional fuel vehicles was 232,000, down by 15% yoy. The gross margin of the car sector was 21.9%, with the operating profit margin being around 4.7%. Overall, the contribution from the car sector throughout the year remained stable, slightly down by 3.6% yoy, accounting as much as 56% of total operating profits. The car sector was still the biggest result contributor.

The mobile phone sector was impacted by the fierce price competition of metal parts in 2019. The gross margin dropped by 9.4% to 3.2 ppts, the operating profit margin fell by 3 ppts to 3.4%, and the operating profit contribution of the mobile phone sector decreased by 33% yoy.

The PV market was obviously rebounding. The cell/PV business increased to a certain extent, with revenue being up by 12% yoy.

Epidemic Resulted in Pressure in 2020 Q1 Results of the Car Sector

In Q1 2020, the Company reported a revenue of RMB19,679 million, down by 35.1% yoy. Net profit was RMB113 million, down by 85% yoy. Given that the mobile phone business of BYD E(285.HK) recorded net profit of RMB660 million, it can be deduced that the car sector and cell/PV sector generated a loss of around RMB320 million.

Impacted by the epidemic, the sales volume of cars of the Company was 61,000, down by 48% yoy. Among them, new energy vehicles was 22,000, down by 70% yoy, and 39,000 fuel vehicles were sold, down by 12% yoy. The epidemic seriously impacted the production capability utility rate and gross margin of the car sector. Luckily, some of the impact was set off by the increase of 4.4 ppts of gross margin in the mobile phone sector. Thus the overall gross margin of the Company dropped by 1.4 ppts.

Result Guidance Indicates the Significant Improvement of Results in Q2

Meanwhile, the Company predicts that the net profit attributable to the parent company from January to June in 2020 will be RMB1.6 billion to RMB1.8 billion, up by 10% to 23.75% yoy. This is mainly because of the significant improvement in the profitability of BYD Electronic, the Company's subsidiary. There will be no less than a 280% of increase yoy. In other words, the mobile phone sector will contribute at least RMB1 billion of net profit in Q2. Based on this, in Q2, net profit of the car sector and cell/PV sector will be between RMB487 million and RMB687 million, which will be a great improvement compared to Q1's loss.

The Company suggests that the reason for the great increase of profits in Q2 are:

1) With the gradual disappearance of impact of the epidemic in China, the car industry will recover steadily. The subsidy policies are relatively positive. The sales volume and revenue of new energy vehicles will get out of the trough and experience a recovering increase. Meanwhile, new blade cells and technologies including DMI will be fully launched, which is beneficial to reducing costs and improving profits. In terms of fuel vehicles, led by the hot sale models including "Song pro", it is estimated that the sales volume will be large.

2) With respect to skyrail business, because of the acceleration of infrastructure construction projects of local governments, the business has profited in Q1 and will become a new profit increase engine in the future.

3) As for the mobile sector, the market share of main customers has been increasing and the business scale has been enlarging. Meanwhile, the outcome of introducing new spare parts and accessories is shown and the production volume of mobile phone parts made of glass ceramics and other materials has been increasing rapidly. Therefore, the profitability will be significantly improved in Q2. In addition, mask production will also contribute positively.

4) Regarding the PV sector, impacted by the overseas epidemic, it is estimated that PV business will suffer pressure in Q2.

Investment Thesis

Transformation Pays, Maintaining Accumulate Rating

We believe that the technological progress and transformation of BYD in recent years will activate its overall competitiveness again, which will enable it to enlarge its market shares in the coming reshuffling period. Advance position in a qualified race track, forward-looking layout and outstanding capability to implement are helping the Company to enter a result realizing period with multiple harvest businesses. Therefore, although there are various challenges in the future, we believe that the Company is entering into a growth period with more stability and sustainability.

As the latest estimates, we revise the target price to HKD53, which corresponded to 2.4/2.3x P/B and 65.5/35.5 x P/E ratio for 2020/2021. We give the rating of ¡§Accumulate¡¨. (Closing price as at 7 May)


Sales of NEVs is not as good as expected

Cloud Rail business risk

Slow-down of Hand-set components business


Click Here for PDF format...

Recommendation on 11-5-2020
Price on Recommendation Date$ 47.500
Suggested purchase priceN/A
Target Price$ 53.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]